Relapse of tuberculosis after treatment in human immunodeficiency virus- infected patients

Archives of Internal Medicine

Volumn 157, Issue 2, 1997, Pages 227-232

  Pulido, Federico ^a   Peña, Jose María ^b   Rubio, Rafael ^a   Moreno, Santiago ^c   González, Juan ^b   Guijarro, Carlos ^a   Costa, Jose Ramón ^a   Vázquez, Juan José ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; TUBERCULOSIS;

EID: 1842371507     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.2.227     Document Type: Article

References (26)

1. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ. 1994;72:213-220.
2. Small PC, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrugresistant Mycobacterium tuberculosis in patients with advanced HIV intection. N Engl J Med. 1993;328:1137-1144.
3. Shafer RW, Kim DS, Weiss JP, Quale JM. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore). 1991;70:384-397.
4. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231-235.
5. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med. 1992;326:668-672.
6. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1991;324:289-294.
7. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet. 1995;345:607-610.
8. Perriëns JH, Louis ME, Mukadi IB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;332:779-784.
9. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 1994;149:1359-1374.
10. Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep. 1993;42:1-8.
11. Iseman MD. Is standard chemotherapy adequate in tuberculosis patients infected with HIV? Am J Respir Crit Care Med. 1987;136:1326.
12. Ormerod LP. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the British Thoracic Society. Thorax. 1990;45:403-408.
13. Chaves F, Dronda F, Ortega A, et al. Tuberculosis resistente en una población penitenciaria durante el periodo 1991-1993. Med Clin (Bare). 1995;105:85-88.
14. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1987;36:1S-15S.
15. Breslow N. A generalized Kruskal-Wallis test tor comparing k samples subject to unequal patterns of censorship. Biometrika. 1970;57:579-594.
16. Slutkin G, Scheeler GF, Hopewell PC. The results of 9-month isoniazidrifampin therapy for pulmonary tuberculosis under program conditions in San Francisco. Am J Respir Crit Care Med. 1988;138:1622-1624.
17. Hong Kong Chest Service, British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of combined preparation of isoniazid, rifampin and pyrazinamide. Am J Respir Crit Care Med. 1991;143:700-706.
18. Singapore Tuberculosis Service, British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 1988;137:1147-1150.
19. Castelo A, Jardim JR, Goihman S, et al. Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. Lancet 1989;2:1173-1176.
20. Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med. 1994;150:1499-1502.
21. Perronne C, Ghoubontni A, Leport C, Salmon-Céron B, Bricaire F, Vildé JL, Should pulmonary tuberculosis be an AIDS-defining diagnosis in patients infected with HIV? Tuber Lung Dis. 1992;73:39-44.
22. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try it. N Engl J Med. 1993;328:576-578.
23. Weiss SE, Slocum PC, Biais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179-1184.
24. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med. 1994;330:1703-1709.
25. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in Mew York City: an analysis by DNA fingerprinting and conventional epidemiology methods. N Engl J Med. 1994;330:1710-1716.
26. Pulido F, Peña JM, Rubio R. Treatment of tuberculosis in HIV infected patients in Zaire. N Engl J Med. 1995;333:519-520.